APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 1.5mg capsule bottle

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

rivastigmine hydrogen tartrate, Quantity: 2.4 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

rivastigmine hydrogen tartrate

formulario farmacéutico:

Capsule

Composición:

Excipient Ingredients: titanium dioxide; stearic acid; iron oxide yellow; maize starch; Gelatin; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Vía de administración:

Oral

Unidades en paquete:

100, 56, 500

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Resumen del producto:

Visual Identification: Hard gelatine calsule with yellow, opaque body and yellow opaque cap. Imprinted "APO R1.5" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estado de Autorización:

Licence status A

Fecha de autorización:

2010-07-27